GSK to invest USD 1.2bn in infectious disease battle

The UK drugmaker has joined a string of pharmaceutical firms that are responding to a call of action concerning future drug resistance.
Photo: Daniel Karmann/AP/Ritzau Scanpix
Photo: Daniel Karmann/AP/Ritzau Scanpix
By James Paton, bloomberg

GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading